- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02306044
Bleeding Prediction in Thrombocytopenia
August 26, 2019 updated by: Pernille Just Vinholt
Bleeding Prediction in Thrombocytopenia Using Platelet Indices, Platelet Aggregometry and a Standardized Bleeding Questionnaire
The purpose of the study is to investigate whether platelet indices from automated haematology equipment, whole blood impedance aggregometry and a standardized bleeding questionnaire predict bleeding in admitted patients with thrombocytopenia of various causes.
Study Overview
Status
Completed
Conditions
Detailed Description
Thrombocytopenia is a risk factor for bleeding, but studies concerning markers for stratification of bleeding risk among thrombocytopenic patients are lacking.
This prospective observational cohort study investigates risk factor for bleeding in admitted patients with thrombocytopenia of various causes.
Study Type
Observational
Enrollment (Actual)
280
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Admitted patients with thrombocytopenia of any cause
Description
Inclusion Criteria:
- Admitted patients with thrombocytopenia
- Age ≥18 years
- Platelet count below 80 x109/L
Exclusion Criteria:
- Platelet transfusion within the previous 14 days,
- surgery or trauma within the previous 7 days
- Unable to give informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean platelet volume
Time Frame: 30 days
|
Mean platelet volume (femtolitre (fL))
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Platelet count
Time Frame: 30 days
|
Platelet count ( x10'9/L)
|
30 days
|
immature platelet fraction
Time Frame: 30 days
|
immature platelet fraction (%)
|
30 days
|
Bleeding questionnaire
Time Frame: 30 days
|
Bleeding score based on the condensed MCMDM-1 VWD bleeding questionnaire
|
30 days
|
Platelet aggregation
Time Frame: 30 days
|
Platelet aggregation by Multiplate Analyzer (aggregation units* min)
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pernille J Vinholt, MD, Odense University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
November 24, 2014
First Submitted That Met QC Criteria
December 2, 2014
First Posted (Estimate)
December 3, 2014
Study Record Updates
Last Update Posted (Actual)
August 28, 2019
Last Update Submitted That Met QC Criteria
August 26, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- s-20120088
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopenia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Napolitano MariasantaRegione SiciliaTerminatedThrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy InducedItaly
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada